Cargando…
Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
Autores principales: | Williams, Bryan, Zhang, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255199/ https://www.ncbi.nlm.nih.gov/pubmed/32416786 http://dx.doi.org/10.1016/S0140-6736(20)31131-4 |
Ejemplares similares
-
Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022) -
Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021) -
Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022) -
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020) -
Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)